arrow
F

Francisco Aparisi

Medical Oncology Department
H指数:14
被引数:561

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology

癌症患者靶向治疗、抗体-药物偶联物和免疫治疗的皮肤不良反应的诊断和治疗: 西班牙肿瘤内科学会和西班牙皮肤病与性病学学会的全国共识声明

2026-01-280
OA
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

肺癌幸存者中第二原发癌的发病率:按肿瘤学治疗的西班牙全国前瞻性队列研究

2025-08-120
OA
LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional study

LUDICAS:肺癌患者性功能障碍,一项多中心横断面研究

2025-04-010
OAAI
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
2023-12-011
PRE
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

肺癌患者对SARS-CoV-2的血清阳性率和免疫记忆: 固体研究

2022-01-015
OAAI
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

奥希替尼在西班牙特殊用途药物治疗方案内治疗的晚期EGFR-T790M突变阳性非小细胞肺癌患者中的应用: OSIREX-西班牙肺癌组

2021-03-0610
OAAI
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

具有ROS1重排的晚期肺癌患者血栓形成的高风险

2020-12-0117
PREAI
Analysis of predictive and prognostic soluble biomarkers in advanced non-small cell lung cancer (NSCLC) patients treated with anti-PD1/PDL1
2020-09-010
OAAI
Surgical treatment of bone metastasi: Experience in the General University Hospital of Valencia
2020-09-010
OAAI
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
2018-03-2133
OAAI
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

西班牙携带EGFR突变的晚期NSCLC患者的临床管理和结果

2018-01-3010
OAAI